{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:18:39Z","timestamp":1776838719866,"version":"3.51.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cholangiocarcinoma (CHOL) is a highly aggressive malignancy with a poor prognosis. Homologous recombination deficiency (HRD) is associated with genomic instability and cancer progression, making it a potential therapeutic target. The aim of this study is to develop novel potential prognostic biomarkers and construct an HRD-based prognostic risk prediction model for CHOL to enhance clinical precision medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed HRD across cancers using multiple datasets including TCGA-CHOL, TCGA-LIHC, GDC TARGET-OS, and IMvigor210. HRD scores were calculated using data from Thorsson et\u00a0al. and the maftools R package was used for mutation data visualization and tumor mutational burden (TMB) calculation. Differential gene expression analysis identified HRD-related genes, validated in tumor and adjacent non-tumor tissues using RT-PCR. 10 machine-learning algorithms including RSF, LASSO, GBM, Survival-SVM, SuperPC, Ridge, plsRcox, CoxBoost, Stepwise Cox, Enet were selected to construct a prognostic model and validated in the E-MTAB-6389 and GSE107943. Among them, RSF, LASSO, CoxBoost and Stepwise Cox have the functions of dimension reduction and variable screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparative analysis demonstrated significant associations between HRD scores and genomic instability markers. High HRD scores independently predicted poorer overall survival (log-rank p = 0.043) and progression-free interval (log-rank p = 0.028). Immune infiltration analysis revealed higher levels of active B cells and regulatory T cells in the low-risk group, suggesting differential immune landscapes between risk groups. We identified the CoxBoost and LASSO algorithms as the optimal combination for creating a CoxBoost+ LASSO prognostic model. Using this model, we identified six genes (ANXA2P1, BBOX1, KLHL33, MN1, OR51A4, and TRDN) with significant differential expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our HRD-based prediction model offers a reliable tool for CHOL prognosis, suggesting new potential for six candidate genes as prognostic biomarkers. It highlights potential therapeutic targets and drug sensitivities, providing new insights into personalized treatment strategies for CHOL management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1615657","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:37:44Z","timestamp":1768973864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of prognostic markers related to homologous recombination deficiency in cholangiocarcinoma using CoxBoost and LASSO machine learning techniques"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Liu","sequence":"first","affiliation":[{"name":"Oncology Intervention Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Oncology Intervention Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhao","family":"Shen","sequence":"additional","affiliation":[{"name":"Oncology Intervention Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Yu","sequence":"additional","affiliation":[{"name":"Oncology Intervention Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuying","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Intervention Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinghui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Oncology Intervention Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Hepatopancreatobiliary Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Oncology Intervention Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.21037\/hbsn-21-75","article-title":"Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries","volume":"12","author":"An","year":"2023","journal-title":"Hepatobil Surg Nutr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30073-5","article-title":"Cancer registration in China and its role in cancer prevention and control","volume":"21","author":"Wei","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1457496919832150","article-title":"Differences in prognostic factors and recurrence patterns after curative-intent resection of perihilar and distal cholangiocarcinomas","volume":"109","author":"Sallinen","year":"2020","journal-title":"Scand J Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.sla.0000129492.95311.f2","article-title":"Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma","volume":"240","author":"Jan","year":"2004","journal-title":"Ann Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.241","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s12885-021-08085-z","article-title":"Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)","volume":"21","author":"Grivas","year":"2021","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/oncolo\/oyad216.002","article-title":"ORCHID: a phase II study of olaparib in metastatic renal cell carcinoma patients harborIng a BAP1 or other DNA repair gene mutations","volume":"28","author":"Ged","year":"2023","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2551","article-title":"Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation","volume":"29","author":"Serra-Camprub\u00ed","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0069","article-title":"Heat shock protein 90 is a potential therapeutic target in cholangiocarcinoma","volume":"14","author":"Shirota","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets--update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12072-019-09954-3","article-title":"Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach","volume":"13","author":"Ahn","year":"2019","journal-title":"Hepatol Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1028404","article-title":"Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2022125","article-title":"Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma","volume":"54","author":"Yao","year":"2022","journal-title":"Acta Biochim Biophys Sin"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1175730\/v1","article-title":"Immune infiltration and a ferroptosis-related gene signature for predicting the prognosis of patients with cholangiocarcinoma","volume":"14","author":"Wang","year":"2022","journal-title":"Am J Trans Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s12885-022-09665-3","article-title":"Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.747445","article-title":"A novel ferroptosis-related 4-gene prognostic signature for cholangiocarcinoma and photodynamic therapy","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"bbaa164","DOI":"10.1093\/bib\/bbaa164","article-title":"Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology","volume":"22","author":"Yang","year":"2021","journal-title":"Briefings Bioinf"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.01.001","article-title":"Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma","volume":"163","author":"Zhang","year":"2018","journal-title":"Surgery"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj234","article-title":"Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States","volume":"98","author":"Welzel","year":"2006","journal-title":"J Natl Cancer Institute"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.08.004","article-title":"Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules","volume":"44","author":"Gandou","year":"2013","journal-title":"Hum Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-923-MPOMCI","article-title":"Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas","volume":"131","author":"Kim","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.humpath.2011.04.004","article-title":"Detection of hepatitis B virus DNA in paraffin-embedded intrahepatic and extrahepatic cholangiocarcinoma tissue in the northern Chinese population","volume":"43","author":"Wu","year":"2012","journal-title":"Hum Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/jpm12081270","article-title":"Wnt\/\u03b2-catenin-pathway alterations and homologous recombination deficiency in cholangiocarcinoma cell lines and clinical samples: towards specific vulnerabilities","volume":"12","author":"Scheiter","year":"2022","journal-title":"J Personal Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"154810","DOI":"10.1016\/j.prp.2023.154810","article-title":"BBOX1-AS1: A novel oncogenic long non-coding RNA in human cancers","volume":"250","author":"Zhang","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08981-5","article-title":"Oncogenic fusions converge on shared mechanisms in initiating astroblastoma","volume":"643","author":"Shi","year":"2025","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06734-0","article-title":"Pseudogene Annexin A2 Pseudogene 1 Contributes to Hepatocellular Carcinoma Progression by Modulating Its Parental Gene ANXA2 via miRNA-376a-3p","volume":"66","author":"Ou","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216900","article-title":"Targeting JAK\/STAT pathway in Takayasu\u2019s arteritis","volume":"79","author":"R\u00e9gnier","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/ijms22020733","article-title":"Differential DNA methylation in prostate tumors from puerto rican men","volume":"22","author":"Ruiz-Deya","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3298","article-title":"Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers","volume":"84","author":"Liao","year":"2024","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2551","article-title":"Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation","volume":"29","author":"Serra-Camprub\u00ed","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"19268","DOI":"10.1038\/s41598-021-98948-z","article-title":"Tanshinone IIA affects the Malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"111253","DOI":"10.1016\/j.celrep.2022.111253","article-title":"Arid1a mutation suppresses TGF-\u03b2 signaling and induces cholangiocarcinoma","volume":"40","author":"Guo","year":"2022","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13073-019-0684-0","article-title":"Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response","volume":"11","author":"Mardis","year":"2019","journal-title":"Genome Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1615657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:37:45Z","timestamp":1768973865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1615657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1615657"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1615657","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1615657"}}